6533b7d9fe1ef96bd126b8fe
RESEARCH PRODUCT
Early DEtection of wEaring off in Parkinson disease: The DEEP study
Fabrizio StocchiAngelo AntoniniPaolo BaroneMichele TinazziMaria ZappiaMarco OnofrjStefano RuggieriLetterio MorganteUbaldo BonuccelliLeonardo LopianoPeter PramstallerAlberto AlbaneseMahmood AttarV PosoccoD ColomboGiovanni AbbruzzeseF StocchiL VaccaPp PramstallerM FacherisM GuidottiE MarioG RiboldazziS LevaA PrioriG PezzoliC MargheritaP SoliveriD PiccoF PisanoL ScarzellaA TavellaM ZibettiS OttavianiF ValzaniaS ContarsiR QuatraleM SensiR CeravoloC RossiM CincottaP VanniP Del DottoMg CeravoloM CapecciR MarcheseT TamburiniA ThomasI BorelliR MarconiL GrassoP StanzioneV PisaniAnna Rita BentivoglioGiovanna LoriaMf De PandisG FedericiV ManzoA MauroM PicilloN ModugnoP LambertiC Dell'aquilaG CicarelliA QuattroneG NicolettiA CannasP SollaA NicolettiF MorganteM D'amelioV TerrusoR ElopraM MucchiutM PilleriR BiundiS NassettiR. Micheluccisubject
QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drugdescription
Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on levodopa treatment. Neurologists identified presence of WO in 351 subjects (56.9%), whereas 415 subjects (67.3%) were identified by the self-administered WOQ-19. In patients with a <2.5 years disease duration, WO was diagnosed in 12 subjects (21.8%) by neurologists and in 23 subjects (41.8%) by the WOQ-19. The most frequent WO symptoms, as identified by WOQ-19, were "slowness of movements" (55.8%) and "reduced dexterity" (48.8%). Younger age, female gender, Unified Parkinson's Disease Rating Scale (UPDRS) part II score and duration of anti-Parkinson treatment were found significantly associated with WO. The number of motor (p < 0.0001) and non-motor (p < 0.0001) WO symptoms correlated with PDQ-8 total score. CONCLUSIONS: WO is common already at the early stages of PD and is underestimated by routine neurological clinical evaluation. The number of WO symptoms, both motor and non motor, increases along with disease duration and has a negative impact on patients QoL.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-02-01 |